Regulation Of US Supplement Industry Needs ‘Really Hard Look’ – FDA's Woodcock
Executive Summary
Acting commissioner's comment on supplement industry regulation was her most definitive statement about the agency’s work in consumer health sector at CHPA's regulatory conference. Pandemic, she says, heightened consumer interest in self-care along with demand for OTC drugs and supplements.
You may also be interested in...
As US FDA’s Principal Deputy Commissioner, Woodcock Focusing On Food Issues
Commissioner Robert Califf wants Janet Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.
US Supplement Industry Capitol Hill Champion, Pivotal Drug Legislation Author Orrin Hatch Dies
DSHEA, legislation Congress passed in 1994 establishing framework for FDA’s oversight of supplement manufacturing and marketing, doesn’t bear Hatch’s name. But in US consumer health products industry, his name is probably more frequently linked with DSHEA than with pivotal drug legislation he co-authored.
VMS Market Regulation Gets Targeted Funding In US FDA Budget; OTC Switches Get Question
In report explaining congressional intent for omnibus spending bill, House and Senate appropriators note concerns about, and target $5m for, regulation of supplement market. Question on moving drug ingredients from Rx to nonprescription not accompanied by targeted funding.